Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Business Wire
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include:Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year.Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year.Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024.Net sales of $383.5 million in FY 2024 increased 22% year-over-year.Introduced 2025 net sales guidance of $475 million to $485 million.“Our record fourth quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond,” said Thomas Burns, Glaukos c
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos (NYSE:GKOS) had its price target raised by analysts at Truist Financial Corporation from $120.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
- Glaukos (NYSE:GKOS) was given a new $165.00 price target on by analysts at UBS Group AG.MarketBeat
- Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Glaukos Announces Participation in J.P. Morgan Healthcare ConferenceBusiness Wire
- Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
GKOS
Earnings
- 10/29/25 - Beat
GKOS
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- 12/15/25 - Form 4
- GKOS's page on the SEC website